geoffrey modest medical blogs

  a recent article found that in patients with early breast cancer, statin use after the diagnosis of breast cancer was associated with lower all-cause and breast cancer-specific mortality particularly among patients with hormone receptor-positive subtypes: see breast cancer statin use helps JAMAonc2026 in dropbox, or doi:10.1001/jamanetworkopen.2026.16375 Details : -- 7389 female patients with early invasive breast cancer (BC) in Finland were included in this retrospective population-based cohort study,  based on the Finnish national registries from 1995 and 2013     -- 2313 who were on statins after their BC diagnosis and outcomes were compared to 5076 who were not on statins -- patient characteristics, comparing the groups with breast cancer diagnosis who were on statins after BC diagnosis vs those women having no statins after BC diagnosis:     -- median age: 64 vs 58 yo     -- median follow-up time: 7.4 vs 6.0 years     -- deaths: ...

as a reference to the Lp(a) studies in the pipeline, one of which involved direct PCSK9 effects: enclisiran (which is also spelled inclisiran in the NJM study...), which the FDA unexpectedly (by me) approved without documentation of clinical benefit: https://gmodestmedblogs.blogspot.com/2025/11/oral-pcsk9-improves-all-bad-lipids.html  - -- as a summary of what I have found of several of these Lp(a) inhibitors:     -- muvalapin (oral small-molecule): 63-65% reduction in Lp(a), with benefit within 4 weeks: https://jamanetwork.com/journals/jama/fullarticle/2808864       -- pelacarsen (antisense oligonucleotide that targets the Lp(a) gene): up to 80% reduction in Lp(a):   https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- evinacumab (anti-ANGPTL3 mAb): 16.5% reduction in Lp(a): https://www.sciencedirect.com/science/article/pii/S1933287425003228     -- lomitapide (microsomal triglyceride transf...